We demonstrated the potential of this approach for the treatment of PD using diverse therapeutics (proteins and recombinant DNA) delivered within macrophages in toxin-induced PD mouse models43–48, and transgenic Parkin Q311X(A) mice49. This evidence concerns the gene PRKN and Parkinson disease.